Literature DB >> 11743214

Selected novel anticancer treatments targeting cell signaling proteins.

Y A Elsayed1, E A Sausville.   

Abstract

Empirical approaches to discovery of anticancer drugs and cancer treatment have made limited progress in the cure of cancer in the last several decades. Recent advances in technology and expanded knowledge of the molecular basis of tumorigenesis and metastasis have provided unique opportunities to design novel compounds that rationally target the abnormal molecular and biochemical signals leading to cancer. Several such novel agents have completed advanced stages in clinical development. The excellent clinical results achieved by some of these compounds are creating new paradigms in management of patients with neoplastic diseases. Clinical development of these agents also raises challenges to the traditional methods of drug evaluation and measurement of efficacy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11743214     DOI: 10.1634/theoncologist.6-6-517

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  9 in total

1.  Gossypol inhibits growth, invasiveness, and angiogenesis in human prostate cancer cells by modulating NF-κB/AP-1 dependent- and independent-signaling.

Authors:  Jiahua Jiang; Veronika Slivova; Andrej Jedinak; Daniel Sliva
Journal:  Clin Exp Metastasis       Date:  2011-12-14       Impact factor: 5.150

2.  Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor.

Authors:  Makiko Kobayashi; Ikuko Takahashi-Suzuki; Toshiyasu Shimomura; Yoshikazu Iwasawa; Hiroshi Hirai
Journal:  Invest New Drugs       Date:  2010-06-04       Impact factor: 3.850

Review 3.  Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.

Authors:  Huixin Yu; Neeltje Steeghs; Cynthia M Nijenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

4.  A recombined protein (rSj16) derived from Schistosoma japonicum induces cell cycle arrest and apoptosis of murine myeloid leukemia cells.

Authors:  Fan Yang; Xi Sun; Jia Shen; Li-Ping Yu; Jin-Yi Liang; Huan-Qin Zheng; Zhong-Dao Wu
Journal:  Parasitol Res       Date:  2013-01-15       Impact factor: 2.289

5.  Dynamic contrast-enhanced MRI for monitoring antiangiogenic treatment: determination of accurate and reliable perfusion parameters in a longitudinal study of a mouse xenograft model.

Authors:  Youngkyu Song; Gyunggoo Cho; Ji-Yeon Suh; Chang Kyung Lee; Young Ro Kim; Yoon Jae Kim; Jeong Kon Kim
Journal:  Korean J Radiol       Date:  2013-07-17       Impact factor: 3.500

6.  Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA.

Authors:  Gábor Boros; Edit Miko; Hiromi Muramatsu; Drew Weissman; Eszter Emri; Gijsbertus T J van der Horst; Andrea Szegedi; Irén Horkay; Gabriella Emri; Katalin Karikó; Éva Remenyik
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

7.  In vivo acute toxicity evaluation and in vitro molecular mechanism study of antiproliferative activity of a novel indole Schiff base β-diiminato manganeseIII complex in hormone-dependent and triple negative breast cancer cells.

Authors:  Reyhaneh Farghadani; Maryam Seifaddinipour; Jayakumar Rajarajeswaran; Mahmood Ameen Abdulla; Najihah Binti Mohd Hashim; Si Lay Khaing; Nur'ain Binti Salehen
Journal:  PeerJ       Date:  2019-10-07       Impact factor: 2.984

8.  Structure-Activity Relationship of Synthetic 2-Phenylnaphthalenes with Hydroxyl Groups that Inhibit Proliferation and Induce Apoptosis of MCF-7 Cancer Cells.

Authors:  Chi-Fen Chang; Ci-Yi Ke; Yang-Chang Wu; Ta-Hsien Chuang
Journal:  PLoS One       Date:  2015-10-22       Impact factor: 3.240

9.  Combination of TPF regimen and cinobufotalin inhibits proliferation and induces apoptosis in human hypopharyngeal and laryngeal squamous cell carcinoma cells.

Authors:  Xixi Shen; Yong Tao; Yifan Yang; Ru Wang; Jugao Fang; Meng Lian
Journal:  Onco Targets Ther       Date:  2018-12-31       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.